<DOC>
	<DOC>NCT02274961</DOC>
	<brief_summary>This clinical study hypothesized that S-pantoprazole 10mg would be effective to treat Non erosive Reflux Disease than placebo.</brief_summary>
	<brief_title>S-pantoprazole 10mg Phase III Clinical Study</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<criteria>Adults between the ages of 19 and 75 inclusive Patient with a history of heartburn or acid regurgitation for at least 3 months. Those with episodes of heartburn for 2 days or more during the last 7 days prior to baseline Patients negative for erosive esophagitis confirmed by esophagogastroduodenoscopy(EGD) performed within 7 days of screening Capable of providing written informed consent, willing and able to a comply with all procedures of the study History of endoscopic erosive esophagitis(EE) at screening EGD. Historical evidence of the following disease/conditions : symptom of Irritable bowel syndrome More tha 3cm endoscopic Barrett's esophagus or significant dysplastic changes in the esophagus Proton Pump Inhibitor(PPI) within 4 weeks prior to the baseline visit H2receptor antagonist, sucralfate, prokinetics, Non Steroidal Antiinflammatory Drugs(NSAIDs) (except low dose aspirin) during the 2 weeks prior to the screening Historical evidence of the following disease/conditions during 3 months: ZollingerEllison syndrome, the primary esophageal motility disorders achalasia, esophageal stricture, pancreatitis, gastric ulcer, evidence of upper G.I. malignancy, pancreatitis, malabsorption, severe cardiovascular or pulmonary disease, severe liver disease, severe renal disease, cerebral vascular disease, Known hypersensitivity to any component of drug pregnancy or lactation (F only)</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>